Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition

Neurobiology of Disease

Volumn 46, Issue 1, 2012, Pages 225-233

  Fusco, Francesca R ^a   Anzilotti, Serenella ^a   Giampà, Carmela ^a   Dato, Clemente ^b   Laurenti, Daunia ^a   Leuti, Alessandro ^a   Colucci D'Amato, Luca ^e   Perrone, Lorena ^c   Bernardi, Giorgio ^a,d   Melone, Mariarosa A B ^b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Mediterranée University   (France)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

ERK; Huntington's disease; Immunohistochemistry; R6 2; Rolipram

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PARVALBUMIN; PHOSPHODIESTERASE IV; ROLIPRAM;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN TISSUE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; HUNTINGTON CHOREA; IMMUNOFLUORESCENCE TEST; INTERNEURON; MALE; MOLECULAR PATHOLOGY; MOUSE; NERVE PROJECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRIATE CORTEX; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHODIESTERASE 4 INHIBITORS; ROLIPRAM;

EID: 84858151215     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.01.011     Document Type: Article

References (73)

1. Albin R.L., Reiner A., Anderson K.D., Penney J.B., Young A.B. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 1990, 27(4):357-365.
2. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 1990, 322(18):1293-1298.
3. Albin R.L., Reiner A., Anderson K.D., Dure L.S., Handelin B., Balfour R., et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992, 31(4):425-430.
4. Andrew S.E., Goldberg Y.P., Kremer B., Telenius H., Theilmann J., Adam S., et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 1993, 4(4):398-403.
5. Aoki K., Yamada M., Kunida K., Yasuda S., Matsuda M. Processive phosphorylation of ERK MAP kinase in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(31):12675-12680.
6. Baillie G.S., MacKenzie S.J., McPhee I. Houslay MD Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br. J. Pharmacol. 2000, 131(4):811-819.
7. Bhat N.R., Zhang P. Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death. J. Neurochem. 1999, 72(1):112-119.
8. Canals J.M., Checa N., Marco S., Akerud P., Michels A., Pérez-Navarro E., et al. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striataltarget area. J. Neurosci. 2001, 21(1):117-124.
9. Chen Q., Veenman L., Knopp K., Yan Z., Medina L., Song W.J., et al. Evidence for the preferential localization of glutamate receptor-1 subunits of AMPA receptors to the dendritic spines of medium spiny neurons in rat striatum. Neuroscience 1998, 83(3):749-761.
10. Chu C.T., Levinthal D.J., Kulich S.M., Chalovich E.M., DeFranco D.B. Oxidative neuronal injury. The dark side of ERK1/2. Eur. J. Biochem. 2004, 271(11):2060-2066.
11. Cicchetti F., Parent A. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons. Mov. Disord. 1996, 11:619-626.
12. Colucci-D'Amato L., Perrone-Capano C., di Porzio U. Chronic activation of ERK and neurodegenerative diseases. Bioessays 2003, 25:1085-1095.
13. Corominas M., Roncero C., Ribases M., Castells X., Casas M. Brain-derived neurotrophic factor and its intracellular signaling pathways in cocaine addiction. Neuropsychobiology 2007, 55(1):2-13.
14. de la Monte S.M., Vonsattel J.P., Richardson E.P. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 1988, 47:516-525.
15. DeMarch Z., Giampà C., Patassini S., Martorana A., Bernardi G., Fusco F.R. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol. Dis. 2007, 25(2):266-267.
16. DeMarch Z., Giampà C., Patassini S., Bernardi G., Fusco F.R. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2008, 30(3):375-387.
17. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230(4725):561-563.
18. Ferrante R.J., Kowall N.W., Richardson E.P., Bird E.D., Martin J.B. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neurosci. Lett. 1986, 71(3):283-288.
19. Ferrante R.J., Kowall N.W., Beal M.F., Martin J.B., Bird E.D., Richardson E.P. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 1987, 46(1):12-27.
20. Ferrer I., Friguls B., Dalfó E. Planas AM Early modifications in the expression of mitogen activated protein kinase (MAPK/ERK), stress-activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia. Acta Neuropathol. 2003, 105(5):425-437.
21. Figueredo-Cardenas G., Chen Q., Reiner A. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp. Neurol. 1997, 146(2):444-457.
22. Figueredo-Cardenas G., Harris C.L., Anderson K.D., Reiner A. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp. Neurol. 1998, 149(2):356-372.
23. Frödin M., Peraldi P., Van Obberghen E. Cyclic AMP activates the mitogen-activated protein kinase cascade in PC12 cells. J. Biol. Chem. 1994, 269(8):6207-6214.
24. Fukunaga K., Miyamoto E. Role of MAP kinase in neurons. Mol. Neurobiol. 1998, 16(1):79-95.
25. Fusco F.R., Chen Q., Lamoreaux W.J., Figueredo-Cardenas G., Jiao Y., Coffman J.A., et al. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 1999, 19(4):1189-1202.
26. Fusco F.R., Viscomi M.T., Bernardi G., Molinari M. Localization of ataxin-2 within the cerebellar cortex of the rat. Brain Res. Bull. 2001, 56(3-4):343-347.
27. Fusco F.R., Zuccato C., Tartari M., Martorana A., De March Z., Giampà C., et al. Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. Eur. J. Neurosci. 2003, 18(5):1093-1102.
28. Giampà C., DeMarch Z., D'Angelo V., Morello M., Martorana A., Sancesario G., et al. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease. Eur. J. Neurosci. 2006, 23(1):11-20.
29. Giampà C., Middei S., Patassini S., Borreca A., Marullo F., Laurenti D., et al. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci. 2009, 29(5):902-910.
30. Giampà C., Laurenti D., Anzilotti S., Bernardi G., Menniti F.S., Fusco F.R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 2010, 5(10):e13417.
31. Gómez-Santos C., Ferrer I., Reiriz J., Viñals F., Barrachina M., Ambrosio S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SHSY5Y cells. Brain Res. 2002, 935(1-2):32-39.
32. Gratacòs E., Pérez-Navarro E., Tolosa E., Arenas E., Alberch J. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. J. Neurochem. 2001, 78(6):1287-1296.
33. Hardingham G.E., Cruzalegui F.H., Chawla S., Bading H. Mechanisms controlling gene expression by nuclear calcium signals. Cell Calcium 1998, 23(2-3):131-134.
34. Hetman M., Kanning K., Cavanaugh J.E., Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J. Biol. Chem. 1999, 274(32):22569-22580.
35. Hoffmann R., Baillie G.S., MacKenzie, Yarwood S., Houslay M.D. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 1999, 18(4):893-903.
36. Jiang H., Nucifora F.C., Ross C.A., DeFranco D.B. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associ ated with degradation of CREB-binding protein. Hum. Mol. Genet. 2003, 12:1-12.
37. Jovanovic J.N., Benfenati F., Siow Y.L., Sihra T.S., Sanghera J.S., Pelech S.L., et al. Neurotrophins stimulate phosphorylation of synapsin I by MAP kinase and regulate synapsin I-actin interactions. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(8):3679-3683.
38. Kazantsev A., Preisinger E., Dranovsky A., Goldgaber D., Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(20):11404-11409.
39. Kim J.Y., Kim Y.J., Lee S., Park J.H. The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells. BMC Cancer 2009, 9:27.
40. Kingsbury T.J., Krueger B.K. Ca2+, CREB and krüppel: a novel KLF7-binding element conserved in mouse and human TRKB promoters is required for CREB-dependent transcription. Mol. Cell. Neurosci. 2007, 35(3):447-455.
41. Kleiman R.J., Kimmel L.H., Bove S.E., Lanz T.A., Harms J.F., Romegialli A., et al. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signalling pathways implicated in Huntington's disease. J. Pharmacol. Exp. Ther. 2011, 336(1):64-76.
42. Liebelt B., Papapetrou P., Ali A., Guo M., Ji X., Peng C., et al. Exercise preconditioning reduces neuronal apoptosis in stroke by up-regulating heat shock protein-70 (heat shock protein-72) and extracellular-signal-regulated-kinase. Neuroscience 2010, 166(4):1091-1100.
43. Liévens J.C., Woodman B., Mahal A., Bates G.P. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol. Cell. Neurosci. 2002, 20(4):638-648.
44. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87(3):493-506.
45. Mantamadiotis T., Lemberger T., Bleckmann S.C., Kern H., Kretz O., Martin Villalba A., et al. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 2002, 31(1):47-54.
46. Matsubara M., Kusubata M., Ishiguro K., Uchida T., Titani K., Taniguchi H. Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions. J. Biol. Chem. 1996, 271(35):21108-21113.
47. Meade C.A., Figueredo-Cardenas G., Fusco F., Nowak T.S., Pulsinelli W.A., Reiner A. Transient global ischemia in rats yields striatal projection neuron and interneuron loss resembling that in Huntington's disease. Exp. Neurol. 2000, 166(2):307-323.
48. Melone M.A., Jori F.P., Peluso G. Huntington's disease: new frontiers for molecular and cell therapy. Curr. Drug Targets 2005, 6(1):43-56.
49. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291(5512):2423-2428.
50. Numakawa T., Suzuki S., Kumamaru E., Adachi N., Richards M., Kunugi H. BDNF function and intracellular signaling in neurons. Histol. Histopathol. 2010, 25(2):237-258.
51. Perrone L., Melone M. New targets for therapy in polyglutamine (polyQ) expansion diseases. Curr. Drug Ther. 2008, 3:177-189.
52. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(15):5733-5737.
53. Roze E., Betuing S., Deyts C., Marcon E., Brami-Cherrier K., Pagès C., et al. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. FASEB J. 2008, 22(4):1083-1093.
54. Sevetson B.R., Kong X., Lawrence J.C. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10305-10309.
55. Sgambato V., Pagès C., Rogard M., Besson M.J., Caboche J. Extracellular signal-regulated kinase (ERK) controls immediate early gene induction on corticostriatal stimulation. J. Neurosci. 1998, 18(21):8814-8825.
56. Shimohata T., Nakajima T., Yamada M., Uchida C., Onodera O., Naruse S., et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 2000, 26(1):29-36.
57. Stanciu M., DeFranco D.B. Prolonged nuclear retention of activated extracellular signalregulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J. Biol. Chem. 2002, 277(6):4010-4017.
58. Stanciu M., Wang Y., Kentor R., Burke N., Watkins S., Kress G., Reynolds I., Klann E., Angiolieri M.R., Johnson J.W., DeFranco D.B. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. 2000, 275(16):12200-12206.
59. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(12):6763-6768.
60. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413(6857):739-743.
61. Sun Z., Xie J., Reiner A. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease. Exp. Neurol. 2002, 176(1):55-65.
62. Sun Z., Del Mar N., Meade C., Goldowitz D., Reiner A. Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease. Neurobiol. Dis. 2002, 11(3):369-385.
63. A novel gene containing a trinucleotide repeat is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
64. Vanhoutte P., Barnier J.V., Guibert B., Pagès C., Besson M.J., Hipskind R.A., Caboche J. Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated kinase-dependent pathway in brain slices. J. Mol. Cell Biol. 1999, 19(1):136-146.
65. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57(5):369-384.
66. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44(6):559-577.
67. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
68. Walton M., Young D., Sirimanne E., Dodd J., Christie D., Williams C., et al. The role of the cyclic AMP-responsive element binding protein (CREB) in hypoxic-ischemic brain damage and repair. Brain Res. Mol. Brain Res. 1996, 43:21-29.
69. Walton M., Connor B., Lawlor P., Young D., Sirimanne E., Gluckman P., et al. Neuronal death and survival in two models of hypoxic-ischemic brain damage. Brain Res. Brain Res. Rev. 1999, 29(2-3):137-168.
70. Yao H., Peng F., Fan Y., Zhu X., Hu G., Buch S.J. TRPC channel-mediated neuroprotection by PDGF involves Pyk2/ERK/CREB pathway. Cell Death Differ. 2009, 16:1681-1693.
71. Yu C., Yezierski R., Joshi A., Raza K., Geddes J. Involvement of ERK2 in traumatic spinal cord injury. J. Neurochem. 2010, 113:131-142.
72. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81(5-6):294-330.
73. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293(5529):493-498.